SUSVIMO J Code: J2779

Drug & Product Overview

HCPCS Descriptor Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

HCPCS Added Date July 1, 2022

Manufacturer Genentech

Route of Administration Intravitreal

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About SUSVIMO

Susvimo is a medication aligned to the HCPCS J Code: J2779 for billing, pricing, and reimbursement purposes in the United States. It is an Ophthalmology drug administered via the intravitreal route and manufactured by Genentech.

According to CMS Drug Use Information: This medication implant is used to treat certain serious eye conditions (such as age-related macular degeneration, diabetic macular edema, diabetic retinopathy). It is used by people who have had at least 2 injections of ranibizumab or a similar medication injected into the eye with good results. Ranibizumab works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels. This medication may help prevent decreased vision and blindness.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
50242-0078-12	Susvimo	Genentech, Inc.	100	100 MG / 1 ML
50242-0078-55	Susvimo	Genentech, Inc.	100	100 MG / 1 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

SUSVIMO Pricing & Reimbursement

J2779 Private Payer Reimbursement

$77.23 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

SUSVIMO CPT Administration Codes

CPT Code	Description
67027	Implantation of intravitreal drug delivery system, includes concomitant removal of vitreous
67028	Intravitreal injection of a pharmacologic agent (separate procedure) 67028

JW / JZ modifiers apply

CMS has identified Susvimo (J2779) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

SUSVIMO Medically Unlikely Edits (MUE)

The most billing units of J2779 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.1 mg.

Practitioner Office & Hospital Outpatient

200 units / day

= 20 mg per day

MAI 2 · Date of Service Edit: Policy. Absolute per-day limit set by policy or regulation; units above it are not payable, and denials are not appealable on medical-necessity grounds. See all MUE limits →

SUSVIMO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Neovascular (wet) Age-related Macular Degeneration (AMD)

Drug Class

Vascular Endothelial Growth Factor Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitors [MoA]

Frequently Asked Questions

Is there an available Susvimo billing and coding guide?

Billing and coding information for SUSVIMO can be found through Genentech. Visit Here →

Are there any available Susvimo patient assistance programs?

SUSVIMO patient assistance information can be found through Genentech. Visit Here →

Where can I find Susvimo prescribing information?

SUSVIMO prescribing information can be found at the link below: Visit Here →

Where can I find Susvimo side effect information?

Information regarding SUSVIMO's side effects can be found at MedlinePlus Visit Here →

Does billing SUSVIMO require JZ/JW wastage modifiers?

CMS has identified SUSVIMO(J2779) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.